"
Team:Wageningen UR
From 2012.igem.org
TSlijkhuis (Talk | contribs) |
TSlijkhuis (Talk | contribs) |
||
| Line 57: | Line 57: | ||
<h2 class="ulc2">Social Stream</h2> | <h2 class="ulc2">Social Stream</h2> | ||
| - | <a class="twitter-timeline" href="https://twitter.com/igemwageningen" data-widget-id="245179177588891650">Tweets by @igemwageningen</a> | + | <a class="twitter-timeline" href="https://twitter.com/igemwageningen" data-widget-id="245179177588891650" width="220">Tweets by @igemwageningen</a> |
<script>!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0];if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src="//platform.twitter.com/widgets.js";fjs.parentNode.insertBefore(js,fjs);}}(document,"script","twitter-wjs");</script> | <script>!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0];if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src="//platform.twitter.com/widgets.js";fjs.parentNode.insertBefore(js,fjs);}}(document,"script","twitter-wjs");</script> | ||
Revision as of 15:20, 10 September 2012
P'NAS
Coming soon...
VLPs' origins
Coming soon...
Outside modification
Coming soon...
Inside modification
Coming soon...
Applications
Coming soon...
Abstract
A standardized tool for site specific drug delivery using Virus-Like Particles
Medicines are generally active in a non-site-specific fashion, affecting the whole patient, including healthy tissue. Therefore, we attempt to specifically target diseased areas by packaging medicines inside Virus-Like Particles (VLPs). VLPs are not infectious, as they are built solely from viral coat proteins. We designed a modular Plug and Apply system that enables modifications to these coat proteins. The system facilitates the linkage of numerous ligands to the coat protein, thereby creating site-specific carriers. After expression of coat protein genes in Escherichia coli the VLPs were assembled in vitro, yielding modified Virus-Like Particles. Medicines can be packed using the Plug and Apply system or simply by addition during VLP assembly. Concluding, VLPs can be used as universal carriers for site-specific drug delivery, allowing customization to a variety of diseases while decreasing side effects for patients during treatment.
